Astellas Pharma (4503.T) Stock Price
Astellas Pharma Price
Over the last 19 years Astellas Pharma grew revenue by 4.5% annually, reaching 2.14 T JPY. Earnings per share have grown at 4.3% per year over the last 19 years. For Astellas Pharma, the net margin of 13.6% is up versus 9.6% a few years ago. At today's price the dividend yield works out to roughly 4.58%. The payout ratio is around 381% of earnings. The dividend has grown at 10.3% per year over the past 19 years. The consensus 12-month price target for Astellas Pharma is 2,091.00 JPY, about 16.8% below where the stock trades today. Of 20 analysts, 8 rate the stock a buy — an overall Hold consensus.
Astellas Pharma stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Astellas Pharma business model & stock analysis
Frequently asked questions about Astellas Pharma
The business model of Astellas Pharma Inc, a leading pharmaceutical company, focuses on research, development, manufacturing, and marketing of innovative pharmaceutical products. Astellas Pharma Inc specializes in therapeutic areas such as urology, immunology, nephrology, and oncology. With a patient-centric approach, Astellas strives to improve the health and well-being of people worldwide by delivering breakthrough treatments. They collaborate with healthcare professionals, organizations, and researchers to drive scientific advancements and enhance patient outcomes. Astellas Pharma Inc's dedication to innovation, strategic partnerships, and global expansion sets it apart in the pharmaceutical industry, allowing them to continue making a positive impact on the lives of patients.
Astellas Pharma Inc is primarily active in the pharmaceutical industry. The company specializes in the research, development, manufacturing, and sale of innovative pharmaceutical products. With a focus on therapeutic areas such as oncology, urology, immunology, and infectious diseases, Astellas Pharma Inc aims to improve patients' lives through the discovery of innovative and effective treatments. As a renowned global pharmaceutical company, Astellas Pharma Inc actively collaborates with healthcare professionals, organizations, and academic institutions to advance medical knowledge and provide quality healthcare solutions worldwide.
The main competitors of Astellas Pharma Inc in the market include Pfizer, Johnson & Johnson, Novartis, GlaxoSmithKline, and Merck & Co.
Astellas Pharma Inc. is a leading pharmaceutical company founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Based in Tokyo, Japan, Astellas specializes in the research, development, and commercialization of innovative drugs and medical solutions. With a strong focus on areas such as urology, immunology, and oncology, Astellas has established itself as a global player in the healthcare industry. The company continually strives to improve patient lives through its cutting-edge products and dedication to scientific advancements. Astellas Pharma Inc. remains committed to addressing unmet medical needs and contributing to the overall well-being of communities worldwide.
Astellas Pharma Inc, a renowned pharmaceutical company, has achieved several significant milestones throughout its history. One notable accomplishment is the discovery and development of innovative drugs that have improved the treatment options for various medical conditions. The company has also excelled in creating strategic partnerships with academic institutions, biotech firms, and other pharmaceutical companies to foster research collaboration and enhance its product pipeline. Additionally, Astellas Pharma Inc has successfully expanded its global presence by entering new markets and establishing strong footholds in key regions worldwide. These accomplishments demonstrate Astellas Pharma Inc's commitment to advancing healthcare through groundbreaking research, development, and strategic growth initiatives.
Astellas Pharma Inc is primarily present in various countries and regions worldwide. The company has an extensive global presence, with operations spanning across North America, Europe, Asia, and numerous other regions. Astellas Pharma Inc is actively engaged in pharmaceutical research, development, and commercialization in countries such as the United States, Japan, Europe (including the United Kingdom and Germany), China, and many more. With its commitment to improving the health and well-being of people globally, Astellas Pharma Inc has established a significant presence in key markets around the world.
Astellas Pharma Inc represents values of integrity, dedication, and innovation. With a strong corporate philosophy centered around "Contributing toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products," Astellas Pharma Inc emphasizes the importance of patient well-being and healthcare advancement. Through their research and development efforts, they strive to introduce cutting-edge therapies and medicines to meet unmet medical needs. With an unwavering commitment to ethical conduct and a focus on creating sustainable value, Astellas Pharma Inc demonstrates its dedication to improving global health outcomes.
Analysts currently set an average price target of 2,145.92 JPY for the Astellas Pharma stock (median: 2,091.00 JPY), implying -14.0 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Astellas Pharma stock: 7 recommend buying, 12 holding and 1 selling.
Converted at the current exchange rate, the Astellas Pharma share trades at 14.30 EUR (2,512.00 JPY).
The Astellas Pharma share (4503.T) is listed on 5 stock exchanges, including: Tokio (JPX) (4503.T), Frankfurt (YPH.F), München (YPH.MU), Düsseldorf (YPH.DU).
Astellas Pharma Inc. is a Japanese pharmaceutical company specializing in the development and marketing of innovative therapies for various diseases. The company is divided into three main areas: Pharmaceuticals, OTC products (Non-Prescription products), and Diagnostics.
The revenue of Astellas Pharma is 2.14 T JPY. This figure is based on current financial data and reflects the company's business performance.
The profit of Astellas Pharma is 291.54 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Astellas Pharma is currently 15.48. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Astellas Pharma stock.
The price-to-sales ratio (P/S) of Astellas Pharma is currently 2.11. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Astellas Pharma stock.
The Eulerpool Quality Score for Astellas Pharma is 4/10.
The ISIN of Astellas Pharma is JP3942400007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Astellas Pharma is 856273. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Astellas Pharma is 4503.T. The ticker symbol is used to trade Astellas Pharma shares on the stock exchange.
Astellas Pharma stock
Astellas Pharma Peer Group
Astellas Pharma Ticker
Astellas Pharma FIGI
All fundamentals and in-depth analysis of Astellas Pharma
Our stock analysis for Astellas Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Astellas Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.